Fujifilm initiates a Phase I clinical trial of the anti-cancer agent “FF-21101” (RI labeled antibody) in the United States. PPMX contributed to creating antibody based on antibody engineering technology.
FF-21101 is RI labeled anti CDH3 antibody. Fujifilm has organized the technologies of Group companies to develop FF-21101. Perseus Proteomics (PPMX) contributed to drug-discovery for the antibody.